Post Marketing Study to Evaluate the Safety and Effectiveness of Brolucizumab in Patients With Diabetic Macular Edema. - Trial NCT05959304
Access comprehensive clinical trial information for NCT05959304 through Pure Global AI's free database. This phase not specified trial is sponsored by Novartis Pharmaceuticals and is currently Not yet recruiting. The study focuses on Diabetic Macular Edema. Target enrollment is 66 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Novartis Pharmaceuticals
Novartis
Timeline & Enrollment
N/A
Dec 27, 2023
Jun 26, 2025
Primary Outcome
Incidence and characteristics of treatment-emergent adverse events during the 40 weeks of treatment with Brolucizumab.
Summary
The purpose of this study is to generate additional safety and effectiveness data in Indian
 Diabetic macular edema (DME) patients that more closely resemble the real-world population
 intended to be treated with Brolucizumab. This study is being conducted as part of the
 post-marketing regulatory commitment to the Indian Health authority.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05959304
Non-Device Trial